Navigation Links
Despite claims, UK did not gas Iraqis in the 1920s, new research finds
Date:12/16/2009

It has passed as fact among historians, journalists and politicians, and has been recounted everywhere from tourist guidebooks to the floor of the U.S. Congress: British forces used chemical weapons on Iraqis just after World War I.

But that claim has never been fully squared with the historical record, says R. M. Douglas, a historian at Colgate University. According to Douglas's research, forthcoming in the December issue of The Journal of Modern History, no such incident ever occurred.

Allegations of chemical bombings by the British erupted into the public sphere during the run up to the U.S. invasion of Iraq in 2003. Iraq's history of chemical weapons did not start with Saddam Hussein's gas attack on the Kurds, scholars and critics asserted. It was Great Britain when it controlled the region under League of Nations mandate in the 1920s that first used chemical weapons in the region to quell Arab uprisings. Many scholars went so far as to root Arab distrust of the West in Britain's brutal chemical attacks.

Douglas, however, finds that these claimsoft repeated in books, newspapers and political speechesrest on very shaky foundations.

The first blunt assertion of British chemical weapons use in Iraq comes from a 1986 essay by historian Charles Townshend. In his essay Townshend refers to a 1921 letter penned by J.A. Webster, an official at the British Air Ministry. In Townshend's description, Webster wrote to the British Colonial Office, the overseer of the Mesopotamian occupation, that tear gas shells had been used against Arab rebels with "excellent moral effect."

Douglas's research, however, reveals that Webster was wrong. The army had asked permission to use gas shells, but had not yet employed them in the field. And contrary to Townshend's description of the letter, Webster's much-quoted reference to an "excellent moral effect" represented "the Air Ministry's estimation of what gas bombs dropped from air
'/>"/>

Contact: Kevin Stacey
kstacey@press.uchicago.edu
773-834-0386
University of Chicago Press Journals
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Despite claims, UK did not gas Iraqis in the 1920s, new research finds
2. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
3. European Airports Actively Engaging on Reducing CO2, Despite the Crisis
4. Web of Science(R) Renewals Remain Strong Despite Tough Economic Climate
5. 2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
6. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
7. Healthy Advice Networks Achieves Strong Growth Despite Challenging Economy
8. Global Confidence in Innovation Holds Despite Economy
9. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
10. Fadel Partners Announces 13% Growth Despite IT Services Industry Downtrend
11. Despite Economic Woes, Physician Compensation Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 1, 2015  Turing Pharmaceuticals AG announced that life ... , MD, MSc,  has joined the company as ... Salinas, who holds a medical degree as well ... of significant accomplishments in the pharmaceutical industry, and ... Salinas has played a leadership role in numerous ...
(Date:6/1/2015)... 1, 2015 GenomeDx Biosciences today ... platform, successfully classified various subtypes of bladder ... certain biomarkers, including one type associated with ... genomic signature has potential as a tool ... in patients with muscle-invasive bladder cancers (MIBC). ...
(Date:6/1/2015)... June 1, 2015 Research ... addition of the "Global PDT Machine Industry ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... is a professional and in-depth study on the ... report provides a basic overview of the industry ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Global PDT Machine Industry Report 2014 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... - Dr. Liew awarded Malaysia,s Darjah Yang Mulia ... - GeneNews Limited (TSX: GEN),a company focused on ... of diseases and personalized health management, today,announced that ... Liew,was awarded the Darjah Yang Mulia Pangkuan Negeri ...
... Imprint to Yield a Strong and ... Highly Specific Immune Response, ... ILNS) a biopharmaceutical company focused on,development of disease-modifying therapeutic agents ... announced today,that Dr. Rachel Eren, Vice President Research, will present ...
... Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT),announced that ... than,35% over the first quarter of 2007 exceeding $1,872,000 ... same period in the previous year. Revenues for ... only,$24,374 in the first half of 2006. These significant ...
Cached Biology Technology:GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... for Secure and Resilient Maritime Commerce (CSR) at Stevens Institute ... Stevens was named by the US Department of Homeland Security ... and was selected to lead a national research effort to ... partner with the DHS and serve as an important team ...
... Ind. - One of the most common house ant species ... smallest spaces in a forest, but the ants have found ... Grzegorz Buczkowski, a Purdue University research assistant professor of ... more complex as they move from forest to city and ...
... their wide-view neurostimulator concept a bionic eye that ... technology. The prototype bionic eye, developed by ... and unveiled today at the BVA consortium,s official launch ... of life for patients suffering from degenerative vision loss ...
Cached Biology News:Common house ants form supercolonies, prosper in urban settings 2Bionic Vision Australia puts bionic eye in sight 2
... d1-174 GenBank Accession Number : NM_006225 ... tagged fusion protein corresponding to full length ... pH 7.4, 0.15M NaCl, 0.05% sodium azide ... Quality Assurance: routinely evaluated by immunoblot on ...
Request Info...
Request Info...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: